Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Eparlitozoviril (Apalolithovolrelimab) as Adjuvant Therapy After Resection for Resectable Hepatocellular Carcinoma With Microvascular Invasion (MVI): A Prospective, Single-Center, Phase II Cohort Study

NCT07658105 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT07658105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07658105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Eparlitozoviril (Apalolithovolrelimab) as Adjuvant Therapy After Resection for Resectable Hepatocellular Carcinoma With Microvascular Invasion (MVI): A Prospective, Single-Center, Phase II Cohort Study
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 12, 2026
Completion date
June 30, 2029
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma